Damaged String Biosciences (“Damaged String”), a genomics firm driving the event of the following technology of extra exact, protected, and efficient cell and gene therapies, introduced immediately that it has appointed Steve Becker as Chief Business Officer. An skilled world life sciences government, Steve will information the enlargement of the Firm’s industrial operations and implement a strong go-to-market technique for its Subsequent-Technology Sequencing (NGS)-based DNA break-mapping platform, INDUCE-seq®, because the Firm seems to be to strengthen its place throughout key markets.
Following the shut of its $15M Collection A funding spherical in 2023, Damaged String has been centered on delivering an bold enlargement technique and income development, together with a number of high-profile management appointments. Additional bolstering the chief staff, Steve will direct the commercialization technique for the INDUCE-seq platform to make sure it meets the distinctive wants of the rising cell and gene remedy market, together with the event of a scalable ‘Platform as a Service’ providing an extension of the expertise’s capabilities past gene-editing. He’ll lead the worldwide gross sales and advertising groups, enterprise improvement operate, and technical help operations, together with constructing the Firm’s US industrial operations to nurture its rising community of shoppers and industrial companions.
Steve is a famend chief within the business, with over 30 years of expertise managing various groups to develop scalable market improvement methods throughout start-ups and multi-national organizations. He has efficiently launched quite a few scientific molecular diagnostics assays and spearheaded strategic development initiatives for premier life science instruments firms. He joined Damaged String from Thermo Fisher Scientific, the place he led the licensing and industrial provide channel for the Genetic Sciences and Scientific Oncology NGS divisions. He was liable for constructing industrial partnerships and managing massive contract offers to broaden the Firm’s world buyer base. Earlier than this, he held executive-level positions at Quest Diagnostics, Athena Diagnostics, Inc., and RainDance Applied sciences, in addition to management roles at Agilent Applied sciences and GE Healthcare.
Steve Becker, CCO of Damaged String Biosciences, commented: “What attracted me to Damaged String Biosciences was its game-changing expertise and proficient staff of devoted pioneers altering the way in which we take a look at cell and gene remedy improvement. The Firm is on the forefront of the sector, supporting builders to make sure these transformative therapies can change into a protected actuality for sufferers.” He added: “I’m eager to hit the bottom working as a part of the management staff, to construct strong partnerships and create an distinctive buyer expertise. I’m excited in regards to the position we’ll play in accelerating broad accessibility of cell and gene therapies that can profoundly impression human well being.”
We’re delighted that Steve is becoming a member of us to guide the Firm’s industrial actions primarily based out of Boston, MA. As we enter our subsequent stage of economic development and concentrate on establishing broad adoption of the INDUCE-seq platform, Steve’s help might be pivotal in executing the profitable launch of our industrial providing, in addition to establishing sturdy partnerships with main educational and business gamers within the genomics and cell & gene remedy markets.”
Felix Dobbs, Ph.D., CEO, Damaged String Biosciences
Supply:
